

# Index

*Note:* Page numbers followed by *f* and *t* indicate figures and tables, respectively

## A

- Academic learning, [52](#)
- ADAPT-ITT model, [267](#)
- Adaptive and daily functioning, [54–55](#)
- Adherence measurement, best practices in, [171](#)
  - See also* antiretroviral therapy
  - (ART) adherence
  - electronic monitoring, [173–174](#)
  - pill count/refills, [173](#)
  - self-report, [171–172](#)
  - viral load (VL)/CD-4 count, [174–175](#)
- Adolescents
  - differential impact of HIV/AIDS among, [262–263](#)
  - impact of pediatric HIV on, [98–100](#)
  - living with HIV, [74](#), [75](#), [302](#), [303](#), [310](#)
    - available guidance and assistance to help, [214](#)
    - cultural considerations in working with, [179–180](#)
    - sexual risk behavior, [279f](#)
  - adolescents and young adults (AYAs), [164](#)
    - HIV medication adherence in, [169](#), [170–171](#), [180](#), [181](#)
- Agency for Healthcare Research and Quality Report (AHRQ), [263](#)
- AIDS-free generation, [134](#)
- Americans with Disabilities Act, [139](#)
- AMPLICOR HIV-1 DNA test, [33](#)
- Antenatal care services (ANC), [299](#), [301](#)
- Antiretroviral (ARV) drugs
  - based interventions, [2](#)
  - treatment, [100](#), [101](#)
  - used for HIV therapy, [27t–28t](#)
- Antiretroviral therapy (ART), [4–5](#), [8](#), [25](#), [57–59](#)
  - adherence (*see* Antiretroviral therapy (ART) adherence)
  - (ART) adherence
  - developmental functioning, [45](#)
  - cognitive domains, [47–49](#)
  - global functioning, [45–47](#)
  - infant antiretroviral prophylaxis, [34](#)
  - neonatal dosing for prevention of perinatal transmission, [35t](#)
  - perinatal HIV prevention, [30–34](#)
  - regimens, [190](#), [200](#)
- Antiretroviral therapy (ART) adherence, [29–30](#), [164](#), [166](#)
  - barriers to, in adolescence/young adulthood, [169](#)
    - psychosocial factors, [169–170](#)
    - structural factors, [170](#)
    - treatment regimen, [170](#)
  - barriers to, in childhood, [167](#)
    - psychosocial factors, [167–168](#)
    - treatment regimen, [168](#)
  - facilitators to
    - in adolescence/young adulthood, [170–171](#)
    - in childhood, [168–169](#)
- At-risk groups, targeted interventions for, [147](#)
  - lesbian, gay, bisexual, transgender, and questioning youth, [149](#)
  - sexually active youth, [148](#)
  - young men who have sex with men, [148–149](#)
  - youth
    - who are pregnant, [149–150](#)
    - who use substances, [150](#)

## B

- Barriers
  - to ART adherence in adolescence/young adulthood, [169](#)
    - psychosocial factors, [169–170](#)
    - structural factors, [170](#)
    - treatment regimen, [170](#)
  - and facilitators

- in adolescence/young adulthood, 170–171
- in childhood, 168–169
- Behaviorally acquired HIV (BaHIV/BHIV), 51–52, 79
  - adherence among youth with, 165–166
- Behaviorally infected youth, 24
- Bereavement, 77
- Best practices, 60
- Biology and evolution of HIV infection, 15–16
- Blood–brain barrier, 45
- Buddhism, 118

## C

- CC-chemokine receptor 5 (CCR5), 17
- CD4 count and HIV viral load, 23
- CD4 lymphocyte count, 174
- CD4 T cells, 16, 17
- CDC staging of HIV, 22
- Centers for Disease Control and Prevention (CDC), 262
- Child attributes associated with disclosure, 192–193
- Child development, stigma and, 299–304
- Child disclosure to family, friends, romantic, and sexual partners, 208
- Child HIV-positive status disclosure to child, 198
  - patterns and correlates of, 199–200
- Choosing Life: Empowerment! Action! Results! (CLEAR), 153
- Chronic inflammation and HIV infection, 18
- +Click, 178
- Clinical course and manifestations of HIV infection, 19
- Clinic-based interventions, 176
- Clinicians, culturally relevant issues for, 265–266
- CNS penetration effectiveness (CPE) of regimens, 58–59
- Cognitive behavioral therapy (CBT), 152
- Cognitive concerns, 136
- Cognitive difficulties, 60
- Co-infection with tuberculosis (TB), 20
- Co-learning, 231
- Combination antiretroviral therapy (cART), 1
- Community-based interventions, 148
- Community-based participatory research (CBPR), 154
- Comprehensive policy on HIV in schools, 140
- Comprehensive psychoeducational evaluation and academic support, 151
- Comprehensive sexuality education programs, 143–146

- Condom use, 114, 137
- Confidentiality and disclosures, 239
  - best practices, 241
  - consent conference, 242
  - disclosing confidential information in response to client/patient risk behavior, 233–234
  - establishing confidentiality limits at outset of therapy, 242
  - parental requests for information, 242–243
  - developmental and family factors, 240–241
  - moral and legal frameworks, 239–240
- Connection with adult who cares, 152
- Conners' Parent Rating Scale, 138
- Consent conference, 237, 242
- Contact tracing, 282
- Coping with HIV infection, 96
- Cultural considerations
  - differential impact of HIV/AIDS among youth, 262–263
  - in working with youth living with HIV, 179–180
- Cultural considerations for pediatric HIV research and practice, 259
  - cultural beliefs and health practices, 264
  - culturally relevant issues for clinicians, 265–266
  - culture, 260–261
    - of youth, 262
  - future directions for research and practice, 266–268
  - mental health, 264–265
    - mental disorder and, 264–265
    - and HIV testing, cultural barriers to, 263–264
- Cultural humility, 246, 267, 268
- CXC-chemokine receptor 4 (CXCR4), 17

## D

- Daily life coping with HIV, 98
- Decisional capacity, 235
- Decision-making, 148, 197, 230, 232–233, 235, 239, 249
- Delivery sites, 115–120
- Developmental and academic considerations, 135–136
- Developmental and CNS impact of HIV, 43
  - cognitive and neurological sequelae, 43–44
  - developmental functioning in era of antiretroviral therapy, 45–49
  - future directions, 60–61
  - neuropathogenesis, 44–45
  - perinatally acquired HIV, 43–49

- Developmental and family factors, 235, 240–241
  - Developmental competencies, 235
  - Developmental illness models, 207–208
  - Developmental risks for children with PHIV, 49
    - behaviorally acquired HIV (BHIV), 51–52
    - prenatal exposure to HIV and ART, 50–51
    - sociodemographic and psychosocial risks, 49–50
  - Differential impact of HIV/AIDS among youth, 262–263
  - Directly observed therapy (DOT), 177
  - Disclosure decisions, 301–302, 303
  - Disclosure of HIV in pediatric populations, 189
    - available guidance and assistance to help, 214
      - recommendations, tools, and strategies, 214–215
    - Blasini intervention, 205
    - child attributes associated with disclosure, 192–193
    - child disclosure to family, friends, romantic, and sexual partners, 208
    - child HIV-positive status disclosure to child, 198
      - patterns and correlates of, 199–200
    - counseling recommendations, 196
    - developmental considerations, 208–209
    - disclosure of HIV status to sexual partners, 217
    - ethical considerations, 216
      - disclosure of child's HIV status to child, 216–217
    - experience of children and adolescents after disclosure, 202–203
    - future directions, 218
    - guidance and assistance available for disclosure to the child, 203
      - developmental illness models, 207–208
      - recommendations, tools, and strategies, 203–207
    - guidance and assistance available for disclosure of parental HIV-positive status, 194–198
    - parental attributes associated with disclosure, 192
    - parental HIV status disclosure
      - disclosure to children, 190
      - outcomes of, 193–194
      - patterns and correlates of, 190–192
    - patterns and correlates of disclosure, 209–210
      - potential for peer-based approaches, 215–216
    - religious and spiritual beliefs and practices, 200
    - self-disclosure, 210–212
      - outcomes of, 212–214
      - parental characteristics associated with, 212
      - physical and psychological outcomes, 214
      - relationship dynamics and stigma, 213
      - self-disclosure, secondary prevention, and sexual relationships, 213
      - social support, 212
      - timing for disclosure, 200–201
      - youth disclose, 209–210
  - Discrimination, 7, 121, 139, 245
  - Disease progression and immunosuppression, 4
  - Dismantling racism, 245
  - Disparities in HIV medication adherence, 164–165
  - DNA nucleic acid tests (NATs), 32
- E**
- Ecological approach for HIV prevention, 277–280
  - Educational policies, HIV-specific, 140
    - comprehensive policy on HIV in schools, 140
    - HIV and sex education, 140–141
  - Education and training, 267
  - Electronic monitoring, 173–174
  - Epidemiology of pediatric HIV infection, 1
    - from 1981 to 2016, 96
    - future directions, 9
    - perinatal HIV infection, 1
      - adolescents and young adults, 6–9
      - natural history of HIV, 3–4
      - perinatally infected children, 3
      - resource-limited settings, 5–6
      - treated with ART, 4–5
  - Ethical considerations for disclosure, 216–217
  - Ethical decisions, 244
  - Evidence-based interventions (EBI), 119
    - for families affected by HIV, 102–110
      - for improving adherence, 175
      - clinic-based interventions, 176
      - home-/community-based interventions, 177
    - interventions incorporating technology, 178–179
    - for youth with HIV, 84–88

Evidence-based school-based HIV prevention programs, [145t](#)  
 Evolution of HIV infection, [15–16](#)  
 Executive functioning (EF), [47–48](#)  
 Exosystem approaches, [279](#), [282–283](#)

## F

Facilitators to ART adherence  
   in adolescence/young adulthood, [170–171](#)  
   in childhood, [168–169](#)  
 Family-2-Family Program, [118](#)  
 Family context, [76–77](#)  
   sexual risk behavior, [275](#)  
 Family Education Rights and Privacy Act (FERPA) of 1974, [139](#)  
 Family-level interventions, [281](#)  
 Family Systems Theory, [198](#)  
 Fear of stigma, [113](#)  
 Feedback, obtaining, [239](#), [242](#)  
 Fourth-generation immunoassay testing, [32](#)  
 Full disclosure, [193](#), [208](#)  
 Functional impact of child and adolescent HIV, [52](#)  
   academic outcomes, [52–53](#)  
   adaptive and daily functioning, [54–55](#)  
   medication management, [53–54](#)  
   substance use and risk behaviors, [55](#)  
   transition to adult HIV care, [56–57](#)

## G

Gay, bisexual, or transgender youth (GBTY), [99](#), [115](#)  
 Gay-Straight Alliances (GSAs), [149](#)  
 Geographical context, [261](#)  
 Goodness-of-fit ethical (GFE) framework, [216–217](#), [229](#)  
   addressing health inequities, [244](#)  
     multicultural competence, [246](#)  
     organization and access, [245](#)  
     research burdens and benefits, [247](#)  
   confidentiality and disclosures, [239](#)  
     best practices, [241–244](#)  
     developmental and family factors, [240–241](#)  
     moral and legal frameworks, [239–240](#)  
   informed consent, [231](#)  
     best practices, [236–239](#)  
     developmental and family factors, [235](#)  
     moral and legal frameworks, [231–235](#)  
   relational ethics and goodness of fit, [230–231](#)  
   sexual health, [247](#)

content of conversation, [249–250](#)  
 initiating conversation, [248–249](#)  
 outcomes of conversation, [250–251](#)

## H

Health and Wellness CBT (H&W CBT), [152](#)  
 Healthcare providers, disclosure by, [201](#)  
 Health Insurance Portability and Accountability Act (HIPAA), [241](#)  
 Health issues, [95](#)  
 Health-related considerations, [75–76](#)  
 Health inequities, addressing, [244](#)  
   multicultural competence, [246](#)  
   organization and access, [245](#)  
   research burdens and benefits, [247](#)  
 Highly active antiretroviral therapy (HAART), [18](#), [23](#), [25](#), [26](#), [30–31](#), [44](#), [134](#), [136](#)  
   adherence to, [29](#)  
 HIV adherence in youth, [163](#)  
   adherence among youth with behaviorally (BaHIV) and perinatally (PaHIV) acquired HIV, [165–166](#)  
   disparities in HIV medication adherence, [164–165](#)  
   rate of HIV and medication adherence, [163–164](#)  
 HIV DNA PCR, [32–33](#)  
 HIV-infected adolescents and young adults, [6–9](#)  
 HIV progression  
   after first year of life, [21–23](#)  
   in first year of life, [19–21](#), [20f](#)  
 HIV qualitative RNA assay, [33](#)  
 HIV-related stigma and children, [297](#)  
   case studies  
     Mary, Lusaka, Zambia, [305–306](#)  
     Ryan White, Indiana, USA, [304–305](#)  
   conceptualization, [298](#)  
   manifestations of stigma, [299t](#)  
   research gaps, [310](#)  
   stigma and child development, [299](#)  
     adolescence and young adulthood, [302–304](#)  
     childhood, [301–302](#)  
     pregnancy, birth, and infancy, [299–301](#)  
   stigma-reduction interventions, [306–310](#)  
 HIV testing, [146–147](#)  
   cultural barriers to, [263–264](#)  
 HIV vaccines, [35–36](#)  
 Home/community-based interventions, [177](#)  
 Homelessness, [99](#)  
 Human rights, [7](#), [217](#), [285](#)

**I**

- Immune reconstitution inflammatory syndrome (IRIS), 26
- Impact of pediatric HIV on families, 95
  - adolescents, 98–100
  - delivery sites, 115–120
  - epidemiology of, 96
  - infants, 96–98
  - intervention approaches, 101–114
  - structural interventions, 120–122
- Individual counseling, 152–153
- Individual level interventions, 308*r*, 310
- Individuals with Disabilities Education Act (IDEA), 139
- Infant antiretroviral prophylaxis, 34
- Infants, impact of HIV on, 96–98
- Informed consent, 231
  - best practices, 236
    - child's autonomy strivings, 238–239
    - family's history of shared decision-making, 238
  - fitting assent procedures to child's cognitive and emotional readiness, 236–237
  - fitting parental permission to parent characteristics and information needs, 237–238
  - developmental and family factors, 235
  - moral and legal frameworks, 231–235
- International and low-resource settings, 81–82
- Interpersonal level interventions, 309*r*, 310
- Intervention approaches, 101–114
- Interventions for developmental delay and impairment, 59
- Interventions incorporating technology, 178–179
- IRB decisions, 153–154

**J**

- Juvenile justice centers, 287

**K**

- Knowledge acquisition, 56

**L**

- Late presentation of HIV, 23
- Legal considerations, 139
- Lesbian, gay, bisexual, transgender, or queer (LGBTQ), 79, 80, 149
- Long-term non-progressors (LTNP), 23
- Low- and middle-income countries (LMIC), 97, 111, 112, 114, 116
- Low-resource settings, 81–82

**M**

- Macrosystem approaches for HIV prevention, 279, 283–284
- Maternal-to-child transmission, 19, 263
- Medical implications of HIV among children and adolescents, 15
  - antiretroviral therapy, 25
    - adherence, 29–30
    - infant antiretroviral prophylaxis, 34
    - neonatal dosing for prevention of perinatal transmission, 35*r*
    - perinatal HIV prevention, 30–34
  - behaviorally infected youth, 24
  - future directions, 35
    - HIV vaccines, 35–36
    - therapeutic and preventive approaches, 35–36
- HIV infection
  - biology and evolution of, 15–16
  - chronic inflammation and, 18
  - clinical course and manifestations of, 19
- HIV pathogenesis, 16–18
- HIV progression
  - after first year of life, 21–23
  - in first year of life, 19–21
- slow progressors, 23
- survival to adulthood, 23–24
- Medication adherence, 76
- Medication Event Monitoring System (MEMS) cap, 173–174
- Medication management, 53–54
- Medication refills, 173
- Medication-related barriers, 75
- Memory, 48–49
- Mental health
  - challenges, 95
  - cultural barriers to, 263–264
  - current status of, 75
  - of diverse youth, pediatric HIV/AIDS and, 262
  - mental disorder and, 264–265
- Mentor Mothers, 112, 115, 117
- Men who have sex with men (MSM) behavior, 7
- Mesosystem, 279
  - approaches for HIV prevention, 280–282
- mHealth (mobile health), 310
- Microsystem, 279
- Minority sexual orientation, 79
- Mobile technologies, 120
- Mode of transmission, 16, 79
- Mother living with HIV (MLH), 96, 112, 118
- Mother-to-child transmission (MTCT), 1, 2, 149

Motivational interviewing (MI), 153  
 Multicultural competence, 246  
 Multisystemic therapy (MST) intervention, 177

## N

National Institutes of Health (NIH), 262  
     National Institute on Minority Health and  
     Health Disparities of (NIMHD/NIH),  
     261  
 Natural history, of HIV, 3–4  
 Neonatal dosing for prevention of perinatal  
 transmission, 35*r*  
 Neurodevelopmental complications of HIV, 57  
     prevention and intervention for, 57  
     antiretroviral therapy, 57–59  
     interventions for developmental delay  
     and impairment, 59  
 Non-randomized controlled trials (non-RCTs),  
 144  
 Nucleic acid amplification tests (NATs), 34

## O

Opportunistic infections (OIs), 19, 22*r*, 24, 44  
 Option B+, 120, 299  
 Organizational level interventions, 309*r*, 310

## P

Paraprofessional Mentor Mothers, 117  
 Parental attributes associated with disclosure,  
 192  
 Parental characteristics associated with  
 self-disclosure, 212  
 Parental HIV status disclosure  
     disclosure to children, 190  
     outcomes of, 193–194  
     patterns and correlates of, 190–192  
 Parental monitoring, 275, 280  
 Parental requests for information, 242–243  
 Parents/primary caregivers, disclosure  
     decisions, 201, 205  
 Partial disclosure, 193, 208  
 Pathogenesis of HIV, 16–18  
 Pediatric psychologists, in STI/HIV prevention,  
 285–286  
 Peer-navigator approaches, 310  
 Peer relationships, 169  
     risk behaviors, 276  
 Peer support, 115–116  
 Peer-to-peer activities, 310  
 People living with HIV/AIDS (PLWHA), 265  
 Perinatal HIV exposure but uninfected  
 (PHEU), 46, 47, 50  
 Perinatal HIV infection, 1, 97

HIV-infected adolescents and young adults,  
 6–9  
 HIV infection treated with ART, 4–5  
     natural history of HIV, 3–4  
     perinatally infected children, 3  
     resource-limited settings, 5–6  
 Perinatal HIV prevention, 30–34  
 Perinatally acquired HIV (PaHIV/PHIV), 43,  
 46, 79, 207  
     adherence among youth with PHIV,  
     165–166  
     cognitive and neurological sequelae, 43–44  
     developmental functioning, in the era of  
     ART, 45  
     cognitive domains, 47–49  
     global functioning, 45–47  
     developmental risks for children with  
     PHIV, 49  
     behaviorally acquired HIV (BHIV),  
     51–52  
     prenatal exposure to HIV and ART,  
     50–51  
     sociodemographic and psychosocial  
     risks, 49–50  
     neuropathogenesis, 44–45  
 Perinatally infected children, 3  
 Philani Intervention Model, 117  
 Physical/medical considerations, 136  
 Pill count/refills, 173  
*Pneumocystis pneumonia* (PCP) prophylaxis,  
 33  
*Pneumocystis jiroveci pneumonia* (PJP), 19  
 Policy level interventions, 309*r*, 310  
 Polymerase chain reaction (PCR) laboratory  
 test, 97  
 Positive STEPS (Strategies To Enhance  
 Problem-Solving Skills), 178–179  
 Post-death challenges, 95  
 Pregnant women, HIV test, 149–150  
 Prenatal exposure to HIV and ART, 50–51  
 Preventing mother-to child transmission  
 (PMTCT) “cascade”, 299, 300, 301  
 Prevention Marketing Initiative (PMI), 281  
 Prevention of HIV among youth, 273  
     applied ecological intervention example,  
     284–285  
     future research, 286–287  
     importance of ecological approach for,  
     277–280  
     intervention approaches that transcend  
     multiple levels, 280  
     exosystem approaches, 282–283  
     macrosystem approaches, 283–284

- mesosystems approaches, 280–282
    - multiple access points, 287
    - predictors of risk behavior, 274
      - family, 275
      - individual, 274–275
      - peers, 276
      - relationships, 275–276
      - society, 276–277
    - role of pediatric psychologists in STI/HIV prevention, 285–286
  - Prevention of mother-to-child transmission (PMTCT), 1, 2, 3, 9, 97
  - Primary prevention efforts, 141, 277
    - comprehensive sexuality education programs, 143–146
    - HIV education for school personnel, 142–143
    - HIV testing, 146–147
    - universal precautions training, 141–142
  - Processing speed, 48
  - Progressive encephalopathy (PE), 44
  - Projects
    - ACCEPT (Adolescents Coping, Connecting, Empowering and Protecting Together), 308*t*
    - Teens & Adults Learning to Communicate (TALC), 117
  - Protective factors for children and youth with HIV, 82–83
  - Provider–parent partnership, 206
  - Psychosocial considerations for children and adolescents with HIV, 73
    - background, 73–75
    - current status of mental health, 75
    - health-related considerations, 75–76
    - international and low-resource settings, 81–82
    - mode of transmission, 79
    - resilience and protective factors, 82–83
    - social considerations, 76
      - bereavement, 77
      - family context, 76–77
      - romantic and sexual relationships, 78–79
      - stigma and social relationships, 77–78
    - transition from pediatric to adult care, 80–81
    - treatment recommendations and interventions, 83–89
  - Psychosocial support, 8
  - Psychotherapy, 152–153
  - Public Law 94–142, 139
- R**
- R5-tropic HIV-1, 17
  - Refill record assessments, 173
  - Relational ethics and goodness of fit, 230–231.
    - See also* Goodness-of-fit ethical (GFE) framework
  - Relationship characteristics, and risk behavior, 275–276
  - Research and practice, future directions for, 180–181, 266–268
  - Researchers, considerations for, 153–155
  - Research gaps, 310
  - Resilience and protective factors, 82–83
  - Resource-limited settings, 5–6
  - Risk behavior, predictors of, 274
    - family, 275
    - individual, 274–275
    - peers, 276
    - relationships, 275–276
    - society, 276–277
  - Romantic and sexual relationships, 78–79
  - RV144 trial, 35
  - Ryan White Comprehensive AIDS Resources Emergency (CARE) Act, 305, 309*t*
- S**
- Safer sex practices, teaching, 251
  - School-based referral programs, 146
  - School-based STI/HIV prevention programs, 286
  - School HIV/AIDS Education Program (SHEP), 144, 146
  - School personnel, HIV education for, 142–143
  - School setting, HIV Prevention and Intervention in, 133
    - considerations for researchers, 153–155
    - developmental and academic considerations, 135–136
    - HIV-specific educational policies, 140
      - comprehensive policy on HIV in schools, 140
      - HIV and sex education, 140–141
    - individualized interventions for students infected with/affected by HIV, 150
    - comprehensive psychoeducational evaluation and academic support, 151
    - individual counseling or psychotherapy, 152–153
    - social support, 151–152
    - legal considerations, 139
    - physical/medical considerations, 136

- School setting, HIV Prevention and Intervention in (*cont.*)  
 primary prevention efforts, 141  
   comprehensive sexuality education programs, 143–146  
   HIV education for school personnel, 142–143  
   HIV testing, 146–147  
   universal precautions training, 141–142  
 school-related considerations, 135  
 social–emotional/behavioral considerations, 136–139  
 targeted interventions for at-risk groups, 147  
   lesbian, gay, bisexual, transgender, and questioning youth, 149  
   sexually active youth, 148  
   young men who have sex with men, 148–149  
   youth who are pregnant, 149–150  
   youth who use substances, 150
- Secondary prevention, 277
- Section 504, Rehabilitation Act of 1973, 139
- Self-disclosure, 210–212  
   outcomes of, 212–214  
   parental characteristics associated with, 212  
   physical and psychological outcomes, 214  
   relationship dynamics and stigma, 213  
   self-disclosure, secondary prevention, and sexual relationships, 213  
   social support, 212
- Self-monitoring, encouraging, 120
- Self-report measures of medication adherence, 171–172
- Seropositive status disclosure, 167, 170
- Serosorting, 114
- Sex education, 140–141
- Sexual health education, 247  
   content of the conversation, 249–250  
   initiating the conversation, 248–249  
   outcomes of the conversation, 250–251
- Sexually active youth, 148
- Sexual partners  
   available guidance and assistance to help disclose to, 214–215  
   disclosure of HIV status to, 208, 217  
   sexual relationships, 114
- Sexually transmitted infections (STIs)  
   /HIV-associated risk behavior, 274–275  
   /HIV prevention, 284  
   pediatric psychologists in, 285–286  
   -preventive behavior, 281–282
- Slow progressors, 23
- Social considerations, 76  
   bereavement, 77  
   family context, 76–77  
   romantic and sexual relationships, 78–79  
   stigma and social relationships, 77–78
- Social ecology of human development, 279
- Social–emotional/behavioral considerations, 136–139
- Social media, 120
- Social relationships, 95, 114
- Social support, 82, 89, 151–152  
   after disclosure, 212
- Society, risk behaviors, 276–277
- Sociodemographic and psychosocial risks, 49–50
- Static encephalopathy, 44
- STEP trial, 35
- Stigma, 113–114, 137  
   associated with HIV and AIDS, 297–298  
   and child development, 299  
     adolescence and young adulthood, 302–304  
     childhood, 301–302  
     pregnancy, birth, and infancy, 299–301  
   -reduction interventions, 306–310  
   and social relationships, 77–78
- Structural interventions, 120–122
- Students infected with/affected by HIV,  
   individualized interventions for, 150  
   comprehensive psychoeducational evaluation and academic support, 151  
   individual counseling/psychotherapy, 152–153  
   social support, 151–152
- Substance abuse and treatment, education about, 150
- Substance use, 150  
   and risk behaviors, 55
- Survival to adulthood, 23–24
- T**
- Tailoring and adaptation, 118
- Teaching, Raising, And Communicating with Kids (TRACK) program, 198
- Therapeutic and preventive approaches, 35–36
- Together for Empowerment Activities (TEA) family intervention, 118
- Transition from pediatric to adult care, 74, 80–81
- Transition to adult HIV care, 56–57
- Treatment recommendations and interventions, 83–89
- Truvada as PrEP, 218



**U**

Universal precautions training, [141–142](#)

**V**

Viral load (VL)/CD-4 count, [174–175](#)

Virologic testing, [32](#)

Visual analogue scale (VAS), [178](#)

**W**

Web-based HIV medication adherence  
intervention, [178](#)

**X**

X4-tropic HIV-1, [17](#)

**Y**

Young men who have sex with men (YMSM),  
[7](#), [148–149](#), [163](#)

Youth as a minority culture, [260](#)

Youth disclose, [209–210](#)

available guidance and assistance to help,  
[214–215](#)

Youth living with HIV (YLH), [99](#), [100](#), [115](#)

Youth Risk Behavior Survey (YRBS), [146](#)

Youth with behaviorally acquired HIV, [79](#), [165](#)

Youth with perinatally acquired HIV, [165–166](#)

Youth's behaviors, monitoring, [120](#)

**Z**

Zidovudine, [34](#), [96](#), [97](#)